Dr. Mark Molloy

Biography

Mark Molloy’s expertise centers on the development and application of proteomic analyses addressing critical problems in the life sciences. His proficiency in mass spectrometry—a core analytical technique—underpins collaborative research in biomedical science, with a particularly strong emphasis on translational cancer research. A major focus of his work is the development of innovative mass spectrometry workflows for quantitative targeted proteomic analyses. This work has enabled the investigation of important questions regarding the molecular characterization of colon, thyroid, pancreatic cancers, melanomas, and lung cancers, ultimately contributing to the identification of prognostic and predictive protein biomarkers. Additionally, he has pioneered new research directions involving high-resolution mass spectrometry for pharmacokinetic monitoring of cancer drug levels in patients, as well as analyses of dried blood spots. Mark's leadership and international standing in the application of proteomics is evidenced by an impressive record of grant success (totaling $42.9 million), a solid publication portfolio of over 150 papers, and Scopus citations exceeding 5,000. He has also successfully supervised 14 HDR student completions. Mark served as Director of the Australian Proteome Analysis Facility from 2010 to 2018, providing expert proteomic infrastructure to approximately 100 external academic and industry end-users annually.

Research Interests

Experience